Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Repurposing of antiviral drugs for COVID-19 and impact of repurposed drugs on the nervous system
Madhura Punekar, Manas M. Kshirsagar, Chaitanya Tellapragada, et al.
Microbial Pathogenesis (2022) Vol. 168, pp. 105608-105608
Open Access | Times Cited: 20

Showing 20 citing articles:

Bovine Serum Albumin Nanoparticle-Mediated Delivery of Ribavirin and Mycophenolic Acid for Enhanced Antiviral Therapeutics
Mayra Alejandra Castañeda Cataña, Andrea P. Rivas Marquina, Martín M. Dodes Traian, et al.
Viruses (2025) Vol. 17, Iss. 2, pp. 138-138
Open Access | Times Cited: 1
Alteration of the blood-brain barrier by COVID-19 and its implication in the permeation of drugs into the brain
Héctor Hernández‐Parra, Octavio D. Reyes‐Hernández, Gabriela Figueroa‐González, et al.
Frontiers in Cellular Neuroscience (2023) Vol. 17
Open Access | Times Cited: 30
Development and therapeutic potential of adaptor-associated kinase 1 inhibitors in human multifaceted diseases
Xin Xin, Yue Wang, Lele Zhang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 248, pp. 115102-115102
Closed Access | Times Cited: 17
New perspective of small-molecule antiviral drugs development for RNA viruses
Shasha Li, Huixia Li, Ruiya Lian, et al.
Virology (2024) Vol. 594, pp. 110042-110042
Closed Access | Times Cited: 5
Neuropsychiatric manifestations of Long COVID
Shashank Saurabh Sinha, Md Shafiqul Bari, P. Tripathi, et al.
Indian Journal of Tuberculosis (2025)
Closed Access
Antivirals for Broader Coverage against Human Coronaviruses
Mia Outteridge, Christine M. Nunn, Kevin M. Devine, et al.
Viruses (2024) Vol. 16, Iss. 1, pp. 156-156
Open Access | Times Cited: 4
Discovery and Rational Optimization of 2, 2'-((1h-Indole-2,3-Diyl) Bis (Thio))Diacetamide as Novel Sars-Cov-2 Rdrp Inhibitors
Yu-Cheng Wang, Yu Shi, Jian‐Yuan Zhao, et al.
(2025)
Closed Access
Discovery and rational optimization of 2, 2′-((1H-indole-2,3-diyl) bis (thio))diacetamide as novel SARS-CoV-2 RdRp inhibitors
Yu Shi, Jian‐Yuan Zhao, Min Li, et al.
Bioorganic & Medicinal Chemistry (2025) Vol. 123, pp. 118153-118153
Closed Access
Comparative Analysis of Neuropsychiatric Adverse Reactions Associated with Remdesivir and Nirmatrelvir/Ritonavir in COVID-19 Treatment: Insights from EudraVigilance Data
Aliteia-Maria Pacnejer, M.E. Negru, Anca Maria Arseniu, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 6, pp. 1886-1886
Open Access
Antiviral activity of singlet oxygen-photogenerating perylene compounds against SARS-CoV-2: Interaction with the viral envelope and photodynamic virion inactivation
Petra Straková, Petr Bednář, Jan Kotouček, et al.
Virus Research (2023) Vol. 334, pp. 199158-199158
Open Access | Times Cited: 12
QbD-Based Stability-Indicating RP-HPLC Method Development and Validation for the Estimation of Favipiravir—An Eco-Friendly Approach
Siri Chandana M., K Sujatha, Ajitha Azhakesan, et al.
Journal of AOAC International (2024) Vol. 107, Iss. 3, pp. 377-386
Closed Access | Times Cited: 3
Potential Inhibitors of Lumpy Skin Disease’s Viral Protein (DNA Polymerase): A Combination of Bioinformatics Approaches
S. H. Zia, Md-Mehedi Sumon, Md-Ashikur Ashik, et al.
(2024)
Open Access | Times Cited: 2
Potential Inhibitors of Lumpy Skin Disease’s Viral Protein (DNA Polymerase): A Combination of Bioinformatics Approaches
S. H. Zia, Md-Mehedi Sumon, Md-Ashiqur Ashik, et al.
Animals (2024) Vol. 14, Iss. 9, pp. 1283-1283
Open Access | Times Cited: 2
Kaempferia parviflora Wall. ex Baker against SARS-CoV-2 spike protein: In silico and in vitro studies
Suhaina Supian, Muhamad Aizuddin Ahmad, Lina Rozano, et al.
Journal of Pharmacy & Pharmacognosy Research (2024) Vol. 12, Iss. 2, pp. 371-381
Open Access | Times Cited: 1
Overview of Antiviral Drug Therapy for COVID-19: Where Do We Stand?
Renata Esposito, Davida Mirra, Liberata Sportiello, et al.
Biomedicines (2022) Vol. 10, Iss. 11, pp. 2815-2815
Open Access | Times Cited: 7
Adverse drug reactions associated with COVID-19 management
Vivek P. Chavda, Payal Dodiya, Vasso Apostolopoulos
Naunyn-Schmiedeberg s Archives of Pharmacology (2024) Vol. 397, Iss. 10, pp. 7353-7376
Closed Access
Which emerging micropollutants deserve more attention in wastewater in the post-COVID-19 pandemic period? Based on distribution, risk, and exposure analysis
Xinhui Xia, Huizhi Mu, Yaqun Li, et al.
The Science of The Total Environment (2024) Vol. 951, pp. 175511-175511
Closed Access
Antivirals and Biologics for Broader Coverage Against Human Coronaviruses
Mia Outteridge, Christine M. Nunn, Kevin M. Devine, et al.
(2023)
Open Access | Times Cited: 1
Against Authority: The Bioethics of Ivermectin Use for COVID-19 Infection
Vasile Astărăstoae, Liliana Rogozea
American Journal of Therapeutics (2023) Vol. 30, Iss. 3, pp. e232-e241
Closed Access
Computational-based strategies to deal with liver injuries induced by the repurposed drugs against SARS-CoV-2
Nasim Bakhtiyari, Sepideh Parvizpour, Yosef Masoudi-Sobhanzadeh, et al.
Informatics in Medicine Unlocked (2023) Vol. 41, pp. 101336-101336
Open Access
Page 1

Scroll to top